Now that Merck's ($MRK) Zilmax feed additive is off the market for a safety study, Eli Lilly's ($LLY) competing drug Optaflexx has seen a surge in demand that may have outstripped its ability to supply it immediately. Lilly's Elanco unit says its supply isn't short, but it's "managing the supply" as it assesses long-term demand. Report